Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Rohit Loomba, Arun J. Sanyal, Atsushi Nakajima, Brent A. Neuschwander-Tetri, Zachary D. Goodman, Stephen A. Harrison, Eric J. Lawitz, Nadege Gunn, Kento Imajo, Natarajan Ravendhran, Takemi Akahane, Bradly Boone, Masayuki Yamaguchi, Arkendu Chatterjee, Giridhar S. Tirucherai, Diane E. Shevell, Shuyan Du, Edgar D. Charles, Manal F. Abdelmalek

Producción científica: Articlerevisión exhaustiva

15 Citas (Scopus)

Resumen

Background & Aims: Pegbelfermin is a polyethlene glycol–conjugated analog of human fibroblast growth factor 21, a nonmitogenic hormone that regulates energy metabolism. This phase 2b study evaluated 48-week pegbelfermin treatment in patients with nonalcoholic steatohepatitis (NASH) and stage 3 (bridging) fibrosis. Methods: The FALCON 1 study (NCT03486899) was a multicenter, randomized (1:1:1:1), double-blind, placebo-controlled study. Patients with biopsy-confirmed NASH and stage 3 fibrosis (N = 197) received weekly subcutaneous pegbelfermin (10, 20, or 40 mg) or placebo injections for 48 weeks. The week 24 primary endpoint was a ≥1-point decrease in fibrosis score without NASH worsening or NASH improvement without fibrosis worsening; pegbelfermin dose response was assessed using a Cochran-Armitage trend test across proportions (1-sided α = 0.05). Secondary/exploratory endpoints included histological and noninvasive measures of steatosis, fibrosis, and liver injury/inflammation. Results: At week 24, the primary endpoint was met by 14% (placebo) vs 24%–31% (pegbelfermin arms); statistical significance was not reached due to lack of pegbelfermin dose response (P =.134). At weeks 24 and 48, more patients who received pegbelfermin had ≥30% relative reductions in hepatic fat fraction (magnetic resonance imaging-proton density fat fraction) vs placebo, although no differences reached statistical significance. In the pegbelfermin arms, improvements in liver fibrosis (magnetic resonance elastography and N-terminal type III collagen propeptide) and liver injury/inflammation (alanine aminotransferase, aspartate aminotransferase) were observed vs placebo. Adverse events occurred at similar frequencies across arms. No treatment-related serious adverse events were observed. Conclusions: The FALCON 1 study did not meet its primary endpoint; a ≥1-point decrease in fibrosis score without NASH worsening or NASH improvement without fibrosis worsening assessed via biopsy. Pegbelfermin was generally well tolerated during 48 weeks of treatment.

Idioma originalEnglish (US)
Páginas (desde-hasta)102-112.e9
PublicaciónClinical Gastroenterology and Hepatology
Volumen22
N.º1
DOI
EstadoPublished - ene 2024

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Huella

Profundice en los temas de investigación de 'Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study'. En conjunto forman una huella única.

Citar esto